AI app aims to empower kidney dialysis patients
NCT ID NCT07300761
First seen Jan 09, 2026 · Last updated Jun 20, 2026 · Updated 27 times
Summary
This study tests whether a smartphone app with artificial intelligence can help people on hemodialysis take better care of themselves. The app provides education on diet, fluid intake, and fistula care, and sends reminders. 76 patients will be randomly assigned to use the app or receive standard care for six weeks, and researchers will measure changes in self-care behaviors and blood test results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SELF CARE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AI-supported mobile education application
What this could lead to
If it works, this could give hemodialysis patients a practical tool to better manage their own care, potentially reducing complications and improving quality of life.
What could go wrong
This is a small, early-stage trial (76 people) testing a behavioral app, not a drug. The results may not be generalizable, and the app's impact on health outcomes is uncertain.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.